Skip to main content

Summary

for people ages 18 years and up
at San Francisco, California and other locations
study started
estimated completion:

Description

Summary

MGCD265 is an orally administered receptor tyrosine kinase inhibitor that targets MET and other receptors. This study is a Phase 2 trial of MGCD265 in patients with locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) that has activating genetic changes of the MET gene (mutation or amplification [increase number of gene copies]). Testing for tumor gene changes can be performed in tumor tissue or blood samples. Patients must have previously received treatment with chemotherapy. The number of patients to be enrolled will depend on how many enrolled patients experience tumor size reduction. MGCD265 will be administered orally, twice daily. The study is designed to evaluate whether the number of patients experiencing tumor size reduction is substantially higher than would be expected with other available treatments.

Official Title

Phase 2, Parallel-Arm Study of MGCD265 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Details

If testing has not already been performed, the study will provide for the testing.

Keywords

Non-Small Cell Lung Cancer Mirati MGCD265 MET NSCLC

Eligibility

You can join if…

Open to people ages 18 years and up

  • Diagnosis of non-small cell lung cancer
  • Metastatic or locally advanced disease
  • Prior platinum chemotherapy or immunotherapy
  • Test result showing genetic change in MET tumor gene
  • At least one tumor that can be measured on a radiographic scan

You CAN'T join if...

  • Prior treatment with inhibitor of MET or HGF
  • Prior positive test for EGFR mutation or ALK gene rearrangement
  • Uncontrolled tumor in the brain

Locations

  • Providence Saint Joseph Medical Center accepting new patients
    Burbank, California, 91505, United States
  • Innovative Clinical Reseach Institute accepting new patients
    Whittier, California, 90603, United States
  • Saint Joseph Heritage Healthcare accepting new patients
    Fullerton, California, 92835-3825, United States
  • Loma Linda University Medical Center accepting new patients
    Loma Linda, California, 92354, United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Mirati Therapeutics Inc.
ID
NCT02544633
Phase
Phase 2
Lead Scientist
Collin Blakely
Study Type
Interventional
Last Updated
June 1, 2017
I’m interested in this study!